340 related articles for article (PubMed ID: 27106406)
1. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
Kothari P; White NS; Farid N; Chung R; Kuperman JM; Girard HM; Shankaranarayanan A; Kesari S; McDonald CR; Dale AM
AJNR Am J Neuroradiol; 2013 Sep; 34(9):1752-1757. PubMed ID: 23578667
[TBL] [Abstract][Full Text] [Related]
3. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
4. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
5. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.
Krishnan AP; Karunamuni R; Leyden KM; Seibert TM; Delfanti RL; Kuperman JM; Bartsch H; Elbe P; Srikant A; Dale AM; Kesari S; Piccioni DE; Hattangadi-Gluth JA; Farid N; McDonald CR; White NS
AJNR Am J Neuroradiol; 2017 May; 38(5):882-889. PubMed ID: 28279985
[TBL] [Abstract][Full Text] [Related]
6. Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).
Farid N; Almeida-Freitas DB; White NS; McDonald CR; Kuperman JM; Almutairi AA; Muller KA; VandenBerg SR; Kesari S; Dale AM
J Neurooncol; 2014 Dec; 120(3):539-46. PubMed ID: 25135423
[TBL] [Abstract][Full Text] [Related]
7. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
Hsu CH; Lober RM; Li MD; Partap S; Murphy PA; Barnes PD; Fisher PG; Yeom KW
J Neurooncol; 2015 May; 122(3):491-6. PubMed ID: 25758812
[TBL] [Abstract][Full Text] [Related]
8. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
[TBL] [Abstract][Full Text] [Related]
9. Normalization of ADC does not improve correlation with overall survival in patients with high-grade glioma (HGG).
Qin L; Li A; Qu J; Reinshagen K; Li X; Cheng SC; Bryant A; Young GS
J Neurooncol; 2018 Apr; 137(2):313-319. PubMed ID: 29383647
[TBL] [Abstract][Full Text] [Related]
10. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
Nowosielski M; Recheis W; Goebel G; Güler O; Tinkhauser G; Kostron H; Schocke M; Gotwald T; Stockhammer G; Hutterer M
Neuroradiology; 2011 Apr; 53(4):291-302. PubMed ID: 21125399
[TBL] [Abstract][Full Text] [Related]
11. Utility of intravoxel incoherent motion magnetic resonance imaging and arterial spin labeling for recurrent glioma after bevacizumab treatment.
Miyoshi F; Shinohara Y; Kambe A; Kuya K; Murakami A; Kurosaki M; Ogawa T
Acta Radiol; 2018 Nov; 59(11):1372-1379. PubMed ID: 29471670
[TBL] [Abstract][Full Text] [Related]
12. Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade.
Kang Y; Choi SH; Kim YJ; Kim KG; Sohn CH; Kim JH; Yun TJ; Chang KH
Radiology; 2011 Dec; 261(3):882-90. PubMed ID: 21969667
[TBL] [Abstract][Full Text] [Related]
13. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
[TBL] [Abstract][Full Text] [Related]
14. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
Chen C; Huang R; MacLean A; Muzikansky A; Mukundan S; Wen PY; Norden AD
J Neurooncol; 2013 Nov; 115(2):267-76. PubMed ID: 23974656
[TBL] [Abstract][Full Text] [Related]
15. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two region-of-interest placement methods for histogram analysis of apparent diffusion coefficient maps for glioma grading.
Hieu ND; Hung ND; Hung ND; Hien MM; Anh DV; Dung LT
Clin Ter; 2024; 175(3):128-136. PubMed ID: 38767069
[TBL] [Abstract][Full Text] [Related]
17. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
[TBL] [Abstract][Full Text] [Related]
18. ADC texture--an imaging biomarker for high-grade glioma?
Brynolfsson P; Nilsson D; Henriksson R; Hauksson J; Karlsson M; Garpebring A; Birgander R; Trygg J; Nyholm T; Asklund T
Med Phys; 2014 Oct; 41(10):101903. PubMed ID: 25281955
[TBL] [Abstract][Full Text] [Related]
19. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
20. Invasion is not an independent prognostic factor in high-grade glioma.
Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
